<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">16938</article-id><article-id pub-id-type="doi">10.36691/RJA16938</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Case reports</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Клинические случаи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Clinical efficacy of modern emollients in atopic dermatitis: case reports</article-title><trans-title-group xml:lang="ru"><trans-title>Клиническая эффективность современных эмолентов у больных атопическим дерматитом: разбор клинических случаев</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1302-4178</contrib-id><name-alternatives><name xml:lang="en"><surname>Smolnikov</surname><given-names>Evgeniy V.</given-names></name><name xml:lang="ru"><surname>Смольников</surname><given-names>Евгений Валентинович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><email>qwertil2010@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5021-9276</contrib-id><name-alternatives><name xml:lang="en"><surname>Litovkina</surname><given-names>Alla O.</given-names></name><name xml:lang="ru"><surname>Литовкина</surname><given-names>Алла Олеговна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><email>dr.litovkina@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4609-2591</contrib-id><name-alternatives><name xml:lang="en"><surname>Elisyutina</surname><given-names>Olga G.</given-names></name><name xml:lang="ru"><surname>Елисютина</surname><given-names>Ольга Гурьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med)</p></bio><bio xml:lang="ru"><p>д-р мед. наук</p></bio><email>el-olga@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3358-5087</contrib-id><name-alternatives><name xml:lang="en"><surname>Fedenko</surname><given-names>Elena S.</given-names></name><name xml:lang="ru"><surname>Феденко</surname><given-names>Елена Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>efedks@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Peoples' Friendship University of Russia</institution></aff><aff><institution xml:lang="ru">Российский университет дружбы народов имени Патриса Лумумбы</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">National Research Center--Institute of Immunology Federal Medical-Biological Agency of Russia</institution></aff><aff><institution xml:lang="ru">Государственный научный центр «Институт иммунологии»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">National Research Nuclear University MEPhI (Moscow Engineering Physics Institute)</institution></aff><aff><institution xml:lang="ru">Национальный исследовательский ядерный университет МИФИ</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2024-04-01" publication-format="electronic"><day>01</day><month>04</month><year>2024</year></pub-date><pub-date date-type="pub" iso-8601-date="2024-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2024</year></pub-date><volume>21</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>177</fpage><lpage>186</lpage><history><date date-type="received" iso-8601-date="2024-03-14"><day>14</day><month>03</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-03-25"><day>25</day><month>03</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Pharmarus Print Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Фармарус Принт Медиа</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Pharmarus Print Media</copyright-holder><copyright-holder xml:lang="ru">Фармарус Принт Медиа</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2026-04-15"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref></license></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/16938">https://rusalljournal.ru/raj/article/view/16938</self-uri><abstract xml:lang="en"><p>Atopic dermatitis is the most common chronic inflammatory skin disease, characterized by itching, chronic recurrent course, and in most cases is associated with respiratory allergies ― allergic rhinitis and asthma. The incidence of atopic dermatitis varies from 15 to 30% or more among children and from 2 to 14% among adults in different countries. The pathophysiological mechanisms of atopic dermatitis are based on a genetic predisposition to allergies, immune dysregulation, and the influence of environmental factors. Recent studies have shown that a key feature of atopic dermatitis is a barrier defects in compromised skin which leads to increased permeability and penetration of environmental factors (e.g., microbes, allergens) and finally to allergen sensitization and to the development of specific allergic inflammation in the target organ ― the skin.</p> <p>The article presents a series of clinical cases of moderate and severe atopic dermatitis, demonstrated an integrated approach to the treatment and selection of emollients, considering the phenotypic features of atopic dermatitis.</p></abstract><trans-abstract xml:lang="ru"><p>Атопический дерматит является одним из самых распространённых кожных заболеваний, характеризуется зудом, хроническим рецидивирующим течением и в большинстве случаев ассоциирован с респираторной аллергией ― аллергическим ринитом и бронхиальной астмой. Заболеваемость атопическим дерматитом в разных странах варьирует в пределах 15–30% и более среди детей и 2–14% среди взрослых. В основе патофизиологических механизмов развития атопического дерматита лежит генетическая предрасположенность к аллергии, дисрегуляция иммунной системы, влияние факторов окружающей среды. Последние исследования показали, что характерной чертой атопического дерматита является нарушение функции эпидермального барьера, приводящее к повышению проницаемости эпидермиса, проникновению аллергенов и микробных агентов через кожу и, в конечном итоге, сенсибилизации к аллергенам и развитию специфического аллергического воспаления в органе-мишени ― коже. Современные терапевтические стратегии помимо воздействия на иммунный ответ направлены на восстановление эпидермального барьера, профилактику сенсибилизации и развития атопического марша.</p> <p>В статье представлена серия клинических случаев среднетяжёлого и тяжёлого течения атопического дерматита, продемонстрирован комплексный подход в лечении и выборе эмолентов с учётом фенотипических особенностей заболевания.</p></trans-abstract><kwd-group xml:lang="en"><kwd>atopic dermatitis</kwd><kwd>epidermal barrier</kwd><kwd>itch</kwd><kwd>xerosis</kwd><kwd>emollients</kwd><kwd>clinical case</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>атопический дерматит</kwd><kwd>эпидермальный барьер</kwd><kwd>зуд кожи</kwd><kwd>ксероз</kwd><kwd>эмоленты</kwd><kwd>клинический случай</kwd></kwd-group><funding-group><funding-statement xml:lang="en">This work was supported by TOPICREM.</funding-statement><funding-statement xml:lang="ru">Работа и подготовка публикации проведены при поддержке TOPICREM.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Atopic dermatitis. Clinical recommendations. Russian Association of Allergists and Clinical Immunologists, Union of Paediatricians of Russia, National Alliance of Dermatovenerologists and Cosmetologists; 2023. (In Russ). Available from: https://raaci.ru/dat/pdf/project_AtD.pdf?ysclid=luehg9eg3q328400965. Accessed: 12.01.2024.</mixed-citation><mixed-citation xml:lang="ru">Атопический дерматит. Клинические рекомендации. Российская ассоциация аллергологов и клинических иммунологов, Союз педиатров России, Национальный альянс дерматовенерологов и косметологов, 2023. Режим доступа: https://raaci.ru/dat/pdf/project_AtD.pdf?ysclid=luehg9eg3q328400965. Дата обращения 12.01.2024.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Reginald K, Westritschnig K, Werfel T, et al. Immunoglobulin E antibody reactivity to bacterial antigens in atopic dermatitis patients. Clin Exp Allergy. 2011;41(3):357–369. doi: 10.1111/j.1365-2222.2010.03655.x</mixed-citation><mixed-citation xml:lang="ru">Reginald K., Westritschnig K., Werfel T., et al. Immunoglobulin E antibody reactivity to bacterial antigens in atopic dermatitis patients // Clin Exp Allergy. 2011. Vol. 41, N 3. Р. 357–369. doi: 10.1111/j.1365-2222.2010.03655.x</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Gaitanis G, Magiatis P, Hantschke M, et al. The Malassezia genus in skin and systemic diseases. Clin Microbiol Rev. 2012;25(1):106–141. doi: 10.1128/CMR.00021-11</mixed-citation><mixed-citation xml:lang="ru">Gaitanis G., Magiatis P., Hantschke M., et al. The Malassezia genus in skin and systemic diseases // Clin Microbiol Rev. 2012. Vol. 25, N 1. P. 106–141. doi: 10.1128/CMR.00021-11</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Simpson EL, Villarreal M, Jepson B, et al. Patients with atopic dermatitis colonized with staphylococcus aureus have a distinct phenotype and endotype. J Invest Dermatol. 2018;138(10):2224–2233. doi: 10.1016/j.jid.2018.03.1517</mixed-citation><mixed-citation xml:lang="ru">Simpson E.L., Villarreal M., Jepson B., et al. Patients with atopic dermatitis colonized with staphylococcus aureus have a distinct phenotype and endotype // J Invest Dermatol. 2018. Vol. 138, N 10. P. 2224–2233. doi: 10.1016/j.jid.2018.03.1517</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Jungersted JM, Hellgren LI, Jemec GB, et al. Lipids and skin barrier function--a clinical perspective. Contact Dermatitis. 2008;58(5):255–262. doi: 10.1111/j.1600-0536.2008.01320.x</mixed-citation><mixed-citation xml:lang="ru">Jungersted J.M., Hellgren L.I., Jemec G.B., Agner T. Lipids and skin barrier function--a clinical perspective // Contact Dermatitis. 2008. Vol. 58, N 5. P. 255–262. doi: 10.1111/j.1600-0536.2008.01320.x</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Wollenberg A, Christen-Zäch S, Taieb A, et al. ETFAD/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–2744. doi: 10.1111/jdv.16892</mixed-citation><mixed-citation xml:lang="ru">Wollenberg A., Christen-Zäch S., Taieb A., et al. ETFAD/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children // J Eur Acad Dermatol Venereol. 2020. Vol. 34, N 12. P. 2717–2744. doi: 10.1111/jdv.16892</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Spergel JM. Epidemiology of atopic dermatitis and atopic march in children. Immunol Allergy Clin North Am. 2010;30(3):269–280. doi: 10.1016/j.iac.2010.06</mixed-citation><mixed-citation xml:lang="ru">Spergel J.M. Epidemiology of atopic dermatitis and atopic march in children // Immunol Allergy Clin North Am. 2010. Vol. 30, N 3. P. 269–280. doi: 10.1016/j.iac.2010.06</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: Part I--systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–1431. doi: 10.1111/jdv.18345</mixed-citation><mixed-citation xml:lang="ru">Wollenberg A., Kinberger M., Arents B., et al. European guideline (EuroGuiDerm) on atopic eczema: Part I--systemic therapy // JEADV. 2022. Vol. 36, N 9. P. 1409–1431. doi: 10.1111/jdv.18345</mixed-citation></citation-alternatives></ref></ref-list></back></article>
